SCHEMBL29567366

SCHEMBL29567366

CC(C)(O)C#Cc1ncc(Cl)cc1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 1/20 0.41
RAF1 P04049 2/20 0.39
MAPT P10636 4/20 0.37
TTBK1 Q5TCY1 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPK1 P28482 2/20 0.35
CNR2 P34972 2/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
ALDH1A1 P00352 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
F10 P00742 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312573 1.00 MAP3K14 (0.41) MAP3K14RAF1MAPTTTBK1TDP1
SCHEMBL26089350 0.85 MAP3K14 (0.41) MAP3K14RAF1MAPTTTBK1CNR2
SCHEMBL30378526 0.85 MAP3K14 (0.41) MAP3K14RAF1MAPTTTBK1CNR2
SCHEMBL24312228 0.83 RAF1 (0.43) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL29566497 0.82 MAPK1 (0.38) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL24312157 0.82 MAPK1 (0.38) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL24312146 0.80 RAF1 (0.38) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL29566145 0.80 RAF1 (0.38) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL24312591 0.80 RAF1 (0.38) RAF1MAPTTDP1MAPK1CNR2
SCHEMBL29610451 0.80 RAF1 (0.38) RAF1MAPTTDP1MAPK1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 US disclosed
US-20220356160-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-11-10 US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 US disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112170-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF MAP3K14 55/4885RAF1 2/4885MAPT 2859/4885
US-11746095-B2 Inhibtors of RAF kinases RAF1, BRAF, ARAF MAP3K14 112/4885RAF1 1/4885MAPT 3440/4885
US-20220356160-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF MAP3K14 55/4885RAF1 2/4885MAPT 2859/4885
US-11377431-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF MAP3K14 55/4885RAF1 2/4885MAPT 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.